ScholarIQanswers from OpenAlex & ORCID
Mark F. Brady
ResearcherPublications, citations & collaboration network
Mark F. Brady is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Mark F. Brady have?
ScholarIQindexed works
Mark F. Brady has 166 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Mark F. Brady have?
ScholarIQcitation count
Mark F. Brady has 20,861 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Mark F. Brady?
ScholarIQh-index
Mark F. Brady has an h-index of 54 in OpenAlex.
What is the i10-index of Mark F. Brady?
ScholarIQi10-index
Mark F. Brady has an i10-index of 92 in OpenAlex.
What is the ORCID of Mark F. Brady?
ScholarIQorcid
The ORCID for Mark F. Brady is on the source record.
What is the OpenAlex record for Mark F. Brady?
ScholarIQopenalex
The OpenAlex for Mark F. Brady is on the source record.
What are the most-cited papers on Mark F. Brady?
ScholarIQmost cited works
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Robert A. Burger, Mark F. Brady, Michael A. Bookman, Gini F. Fleming, Bradley J. Monk, Helen Huang, Robert S. Mannel, Howard D. Homesley, Jeffrey M. Fowler, Benjamin E. Greer, Matthew Boente, Michael J. Birrer, Sharon X. Liang
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
Robert L. Coleman, Gini F. Fleming, Mark F. Brady, Elizabeth M. Swisher, Karina Dahl Steffensen, Michael Friedländer, Aikou Okamoto, Kathleen N. Moore, Noa Ben-Baruch, Theresa L. Werner, Noelle Cloven, Ana Oaknin, Paul DiSilvestro, Mark A. Morgan, Joo‐Hyun Nam, Charles A. Leath, Shibani Nicum, Andrea R. Hagemann, Ramey D. Littell, David Cella, Sally Baron‐Hay, Jesús García-Donás, Mika Mizuno, Katherine M. Bell‐McGuinn, Danielle Sullivan, Bruce Allen Bach, Sudipta Bhattacharya, Christine K. Ratajczak, Peter Ansell, Minh H. Dinh, Carol Aghajanian, Michael A. Bookman
Inherited Mutations in Women With Ovarian Carcinoma
Barbara M. Norquist, Maria I. Harrell, Mark F. Brady, Tom Walsh, Ming K. Lee, Süleyman Gülsüner, Sarah S. Bernards, Silvia Casadei, Yi Qian, Robert A. Burger, John K. Chan, Susan A. Davidson, Robert S. Mannel, Paul DiSilvestro, Heather A. Lankes, Nilsa C. Ramirez, Mary‐Claire King, Elizabeth M. Swisher, Michael J. Birrer
Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup
Michael A. Bookman, Mark F. Brady, William P. McGuire, Peter Harper, David S. Alberts, Michael Friedländer, Nicoletta Colombo, Jeffrey M. Fowler, Peter A. Argenta, Koen De Geest, David G. Mutch, Robert A. Burger, Ann Marie Swart, Edward L. Trimble, Chrisann Accario-Winslow, Lawrence M. Roth
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)
Krishnansu S. Tewari, Michael W. Sill, Richard T. Penson, Helen Huang, Lois M. Ramondetta, Lisa M. Landrum, Ana Oaknin, Thomas Reid, Mario M. Leitão, Helen E. Michael, Philip J. DiSaia, Larry J. Copeland, William T. Creasman, Frederick B. Stehman, Mark F. Brady, Robert A. Burger, J.T. Thigpen, Michael J. Birrer, Steven Waggoner, David H. Moore, Katherine Y. Look, Wui-Jin Koh, Bradley J. Monk